<DOC>
	<DOCNO>NCT01801735</DOCNO>
	<brief_summary>The purpose study evaluate safety Meloxicam SoluMatrix Capsules 52 week subject pain due osteoarthritis ( OA ) knee hip</brief_summary>
	<brief_title>Study Meloxicam Capsules Subjects With Osteoarthritis Knee Hip</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Meloxicam</mesh_term>
	<criteria>Is male female â‰¥ 40 year age If participant previous MEL31202 study , complete study discontinue lack efficacy safety Has diagnosis OA hip knee ongoing knee and/or articular hip pain Chronic user nonsteroidal antiinflammatory drug ( NSAIDs ) and/or acetaminophen OA pain If female childbearing potential , nonlactating nonpregnant History allergic reaction clinically significant intolerance acetaminophen , aspirin , NSAIDs , include meloxicam Requires continuous use opioid opioid combination product control OA pain knee hip Clinically significant unstable cardiac , respiratory , neurological , immunological , hematological , renal disease Significant difficulties swallow capsule unable tolerate oral medication Has receive investigational drug ( except Meloxicam SoluMatrix Capsules ) , device , therapy within 30 day Screening</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>